Estrogen receptor protein (ERP) in multiple tumor specimens from individual patients with breast cancer

Authors:
  • PRPaul Peter Rosen
    Paul Peter Rosen
  • CMCelia J. Menendez-Botet
    Celia J. Menendez-Botet
  • JUJerome A. Urban
    Jerome A. Urban
  • AFAlfred Fracchia
    Alfred Fracchia
  • MSMorton K. Schwartz
    Morton K. Schwartz
Publisher website
Google Scholar
Abstract
We have studied 29 patients from whom two or more spatially and temporally separate samples of breast carcinoma were obtained for ERP analysis. Differences in ERP were obtained in 24% of all cases studied. The greatest degree of variation was found when comparing a primary tumor with a subsequent metastasis (38%). Among eight patients with ERP negative (-) primary tumors, six had ERP (-) and two ERP positive (+) metastases. Among 11 patients with ERP (+) primaries eight had ERP (+) and three ERP (-) metastases. Variations were found in 20% of multiple nonsimultaneous metastases from individual patients. The difference in average interval between cases that did not show variation (9.6 months) and those that did vary (19.3 months) suggests that variation may be more likely to occur with later metastases. However, there was considerable overlap in the range of intervals. These findings underscore the need to biopsy readily accessible recurrences rather than to rely on the results of prior specimens. There was no apparent consistent relationship of these variations to age, site of specimen, interval between specimens or the histologic features of the tissues submitted for analysis. Two patients with an ERP (+) primary tumor had ERP (-) metastases after interval therapy. Similar variations were observed in patients who did not have interval therapy. The data do not perimit any definite conclusions as to the effect of chemotherapy or radiation on the ERP properties of mammary carcinoma.

This publication has 21 references indexed in Scilit: